Related Experiment Videos
[Delayed treatment with dextromethorphan can reduce ischemic retinal damage in rabbit]
1Department of Ophthalmology, School of Medicine, Iwate Medical University, Morioka, Japan.
Nippon Ganka Gakkai Zasshi
|July 1, 1992
Summary
Dextromethorphan (DEX) protects the retina from ischemia when administered immediately after reperfusion. This N-methyl-D-aspartate receptor antagonist shows significant retinal recovery rates in rabbits, highlighting its therapeutic potential.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Context:
- Retinal ischemia can lead to irreversible vision loss.
- N-methyl-D-aspartate (NMDA) receptor antagonists have shown neuroprotective potential.
- Dextromethorphan (DEX) is an NMDA receptor antagonist.
Purpose:
- To investigate the neuroprotective effects of dextromethorphan (DEX) on retinal ischemia.
- To determine the optimal timing for DEX administration following retinal ischemia.
Summary:
- Rabbits received intravenous dextromethorphan (DEX) hydrobromide immediately, 1 hour, or 2 hours after ischemia induced by elevated intraocular pressure.
- Retinal function was assessed using electroretinogram (ERG) 24 hours post-ischemia.
- Immediate DEX administration resulted in significantly higher ERG b-wave amplitude recovery (61.3%) compared to controls (41.9%), while later administration showed no significant benefit.
Impact:
- Dextromethorphan (DEX) demonstrates significant retinal protection when given promptly after ischemia.
- Immediate post-ischemic DEX administration may be a viable therapeutic strategy for preventing vision loss.
- Further research into DEX's role in treating retinal ischemia is warranted.